Intercept Pharmaceuticals, Inc. (ICPT)
-NasdaqGM | Prev Close: | 76.82 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 69.86 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 18-Nov-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 17.96 - 77.53 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 91,053 |
|---|
| Market Cap: | 1.47B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- After-hours buzz: Global Payments, Allstate & moreat CNBC(Tue, Oct 1)
- InPlay: Intercept Pharma announces additional results of Global Primary Biliary Cirrhosis; study group analysis to be presented at AASLD Annual Meeting; Data support strong statistical association of PBC Biochemical endpoint with clinical oBriefing.com(Tue, Oct 1)
- INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other EventsEDGAR Online(Tue, Oct 1)
- Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis to be Presented at AASLD Annual MeetingPR Newswire(Tue, Oct 1)
- 4 Stocks Rising on Unusual Volumeat TheStreet(Mon, Sep 9)
- INTERCEPT PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, Aug 20)
- INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Tue, Aug 13)
- Intercept Pharmaceuticals Reports Second Quarter 2013 Financial ResultsPR Newswire(Tue, Aug 13)
- Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access ConferencePR Newswire(Mon, Aug 5)
- Intercept OCA likely to qualify for accelerated approval, says Oppenheimertheflyonthewall.com(Thu, Jul 11)
- 3 Biotech Stocks Spiking on Big Volumeat TheStreet(Fri, Jul 5)
- CAPScall of the Week: Intercept Pharmaceuticalsat Motley Fool(Tue, Jul 2)
- INTERCEPT PHARMACEUTICALS INC Files SEC form 8-K, Other EventsEDGAR Online(Tue, Jul 2)
- Intercept Pharmaceuticals to Present at the JMP Securities Healthcare ConferencePR Newswire(Mon, Jul 1)
- Intercept Pharmaceuticals Announces Completion of Public Offering and Exercise of Option to Purchase Additional SharesPR Newswire(Mon, Jun 24)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 847.12 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.43 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.51 |
|---|
| Mean Recommendation*: | 1.3 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry.
View More